Metastatic Prostate Cancer Clinical Trials in Nashville, Tennessee

4 studies are recruiting for metastatic prostate cancer in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

    This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermittent high dose testosterone. This therapy may result in responses in tumors which are genetically un…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville, Tennessee
    Locations
    17 in total
    Run by
    VA Office of Research and Development

    See if you can join NCT05011383 on ClinicalTrials.gov

  2. Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC

    This study is a first-in human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX013 in combination with JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Run by
    Janux Therapeutics

    See if you can join NCT07813637 on ClinicalTrials.gov

  3. A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer

    The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-1261 in participants with advanced or metastatic prostate cancer. It's also to identify a recommended dose(s) and regimen for GDC-1261 for subsequent studies.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    5 in total
    Run by
    Genentech, Inc.

    See if you can join NCT07567846 on ClinicalTrials.gov

  4. Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

    Assessment of the safety and efficacy of HLD-0915 (JNJ-101556143) in patients with metastatic prostate cancer who have progressed on prior systemic therapies, with further evaluation in additional prostate cancer populations.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Sarah Cannon Research Institute, Nashville, Tennessee
    Locations
    18 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT06800313 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.